| Establishment and morphological characterization of patient-derived organoids from breast cancer S Mazzucchelli, F Piccotti, R Allevi, M Truffi, L Sorrentino, L Russo, ... Biological procedures online 21, 1-13, 2019 | 62 | 2019 |
| HER-2-targeted nanoparticles for breast cancer diagnosis and treatment L Sitia, M Sevieri, L Signati, A Bonizzi, A Chesi, F Mainini, F Corsi, ... Cancers 14 (10), 2424, 2022 | 28 | 2022 |
| Lipofilling in breast oncological surgery: a safe opportunity or risk for cancer recurrence? F Piccotti, I Rybinska, E Scoccia, C Morasso, A Ricciardi, L Signati, ... International Journal of Molecular Sciences 22 (7), 3737, 2021 | 21 | 2021 |
| Ultrastructural analysis of breast cancer patient-derived organoids L Signati, R Allevi, F Piccotti, S Albasini, L Villani, M Sevieri, A Bonizzi, ... Cancer Cell International 21 (1), 423, 2021 | 16 | 2021 |
| Impact of doxorubicin-loaded ferritin nanocages (FerOX) vs. free doxorubicin on T lymphocytes: a translational clinical study on breast cancer patients undergoing neoadjuvant … M Sevieri, F Andreata, F Mainini, L Signati, F Piccotti, M Truffi, A Bonizzi, ... Journal of Nanobiotechnology 22 (1), 184, 2024 | | 2024 |
| Luminal breast cancer cells growth is sustained by lipoaspirate components obtained specifically from the abdomen M Truffi, I Rybinska, F Piccotti, L Signati, F Bianchi, SM Pupa, E Tagliabue, ... European Journal of Cancer 200, 2024 | | 2024 |
| Publisher Correction: Impact of doxorubicin-loaded ferritin nanocages (FerOX) vs. free doxorubicin on T lymphocytes: a translational clinical study on breast cancer patients … M Sevieri, F Andreata, F Mainini, L Signati, F Piccotti, M Truffi, A Bonizzi, ... Journal of Nanobiotechnology 22, 2024 | | 2024 |
| Carnitine palmitoyltransferase IA: an emerging potential metabolic target to counteract HER2-targeted therapy resistance in HER2-positive breast cancer A Franceschini, LT Castagnoli, TI Triulzi, PA Corsetto, M Dugo, A Belfiore, ... MOLECULAR CANCER THERAPEUTICS 22 (12), 2023 | | 2023 |
| Abstract A039: Carnitine palmitoyltransferase IA: an emerging potential metabolic target to counteract HER2-targeted therapy resistance in HER2-positive breast cancer A Franceschini, LT Castagnoli, TI Triulzi, PA Corsetto, M Dugo, A Belfiore, ... Molecular Cancer Therapeutics 22 (12_Supplement), A039-A039, 2023 | | 2023 |
| 27P Quantitative detection of plasma extracellular vesicles in early and metastatic breast cancer patients using SiMoA technology M Truffi, CF Morasso, S Albasini, F Piccotti, L Signati, A Faiulo, F Sottotetti, ... ESMO Open 8 (1), 2023 | | 2023 |
